Roivant Sciences Ltd. $ROIV Stock Holdings Decreased by SB Investment Advisers UK Ltd.

Key Points

• SB Investment Advisers UK Ltd. reduced its stake in Roivant Sciences by selling 204,819 shares, bringing its total holdings to approximately 61.85 million shares, valued at around $624 million.
• Insider selling has occurred, with CEO Eric Venker selling 100,000 shares for $1.17 million, and major shareholder Vivek Ramaswamy selling over 577,007 shares for approximately $6.61 million.
• Roivant Sciences reported a substantial EPS loss of ($0.31) for the last quarter, missing analyst expectations, while currently holding a consensus "Buy" rating with a target price of $16.50.

SB Investment Advisers UK Ltd. trimmed its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 0.3% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 61,852,718 shares of the company's stock after selling 204,819 shares during the period. Roivant Sciences accounts for approximately 5.7% of SB Investment Advisers UK Ltd.'s holdings, making the stock its 3rd biggest position. SB Investment Advisers UK Ltd. owned approximately 8.67% of Roivant Sciences worth $624,094,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Parallel Advisors LLC raised its holdings in shares of Roivant Sciences by 80.5% during the first quarter. Parallel Advisors LLC now owns 2,485 shares of the company's stock valued at $25,000 after buying an additional 1,108 shares during the last quarter. UMB Bank n.a. grew its holdings in Roivant Sciences by 112.7% in the 1st quarter. UMB Bank n.a. now owns 4,143 shares of the company's stock worth $42,000 after buying an additional 2,195 shares in the last quarter. Russell Investments Group Ltd. increased its position in Roivant Sciences by 94.8% in the 1st quarter. Russell Investments Group Ltd. now owns 4,588 shares of the company's stock valued at $46,000 after acquiring an additional 2,233 shares during the period. Fifth Third Bancorp raised its stake in Roivant Sciences by 59.3% during the 1st quarter. Fifth Third Bancorp now owns 5,118 shares of the company's stock valued at $52,000 after acquiring an additional 1,905 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in Roivant Sciences by 83.0% during the 1st quarter. GAMMA Investing LLC now owns 6,493 shares of the company's stock worth $66,000 after acquiring an additional 2,945 shares during the period. Institutional investors own 64.76% of the company's stock.

Insider Activity at Roivant Sciences

In related news, major shareholder Vivek Ramaswamy sold 577,007 shares of the firm's stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $11.46, for a total transaction of $6,612,500.22. Following the completion of the sale, the insider directly owned 37,284,108 shares in the company, valued at approximately $427,275,877.68. This trade represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Eric Venker sold 100,000 shares of the company's stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $11.72, for a total value of $1,172,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,653,585 shares in the company, valued at $19,380,016.20. This represents a 5.70% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,643,073 shares of company stock worth $18,800,748 in the last ninety days. Corporate insiders own 10.80% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently commented on ROIV shares. HC Wainwright reissued a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a report on Wednesday, June 18th. Citigroup assumed coverage on shares of Roivant Sciences in a research note on Tuesday. They set a "buy" rating and a $16.00 target price on the stock. Finally, The Goldman Sachs Group upgraded shares of Roivant Sciences to a "strong-buy" rating and set a $19.00 price target on the stock in a research report on Thursday, July 10th. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $16.38.

Roivant Sciences Trading Up 1.0%

NASDAQ:ROIV traded up $0.12 during mid-day trading on Wednesday, reaching $12.51. 3,040,851 shares of the stock were exchanged, compared to its average volume of 5,727,955. The business has a fifty day moving average price of $11.51 and a 200 day moving average price of $10.98. Roivant Sciences Ltd. has a 1-year low of $8.73 and a 1-year high of $13.06. The firm has a market capitalization of $8.54 billion, a PE ratio of -17.88 and a beta of 1.15.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.